Objectives: Given concerns regarding optimal therapy for serious Gram-negative infections, the goal was to characterize the pharmacodynamics of ciprofloxacin in the context of treating bloodstream infection.
Introduction
Research over the past few decades has identified the importance of antibiotic pharmacodynamics (PD) in treating infectious diseases. 1 -3 Studies conducted in vitro, in animal models and in humans have characterized complex relationships involving antibiotic pharmacokinetics, pathogen susceptibility and treatment response. Such insights have led to antibiotic dose development, which targets indices such as %T .MIC (percentage of time that concentrations exceed the MIC) for b-lactams, C max /MIC (highest concentration divided by the MIC) for aminoglycosides and AUC 24 /MIC (area under the concentration -time curve over 24 h divided by the MIC) for fluoroquinolones. The conventional AUC 24 /MIC target of ≥125 for ciprofloxacin in treating serious infections is based on original work by Forrest et al., 4 which characterized clinical and microbiological responses based on ciprofloxacin AUC 24 /MIC values. An extensive review by Van Bambeke et al. 5 supported the further study of fluoroquinolone PD, especially the lower targets for optimizing efficacy and minimizing resistance. Moreover, the ability of ciprofloxacin to achieve PD targets given current dosing and susceptibility breakpoints is under question. Amongst concerns in treating serious Gram-negative infections, suggestions have been made to use ciprofloxacin only in combination, to use maximum doses without routine reductions for renal dysfunction and to lower the susceptibility breakpoint, presently an MIC ≤1 mg/L as per the CLSI. 6 -9 In an initial study of ciprofloxacin PD in Pseudomonas aeruginosa bloodstream infection (BSI), 10 we found improved clinical outcomes with higher AUC 24 consistent with the 125 first proposed by Forrest et al. 4 The current study expands our investigation with the goals of characterizing ciprofloxacin PD in treating Enterobacteriaceae BSI and evaluating ciprofloxacin dosing and target attainment in the patient population.
Methods

Clinical cases
The study was conducted at the St Boniface General Hospital (550 bed tertiary care facility) and received approval from the University of Manitoba Health Research Ethics Board. Cases of Enterobacteriaceae BSI were identified using the blood culture database from the Microbiology Laboratory. Only patients with accessible medical records, survival beyond 48 h of their positive blood culture and retrievable isolates were included.
Patient demographics (age, sex, weight and smoking status), renal function [creatinine clearance (CL CR )] and medical history (chronic lung disease, ischaemic heart disease, congestive heart failure, diabetes mellitus, renal or liver disease, malignancy, neutropenia, and invasive procedures within 30 days) were documented. Clinical data including length of hospital stay, healthcare-associated or community-acquired infection, requirements for intensive care unit admission, inotropic support or mechanical ventilation, acute renal failure and additional cultures were also collected. Antibiotic therapy initiated within 72 h of the positive blood culture was detailed according to drug, dose and administration times.
Early clinical response within 72 h was assessed from daily progress notes, temperatures, white blood cell counts and repeat blood cultures when available. Clinical cure meant the resolution of infection-related signs and symptoms without relapse. Treatment failure was persistent fever (≥388C) or positive blood culture exceeding 72 h, or relapse of either. Clinical isolates were retrieved from stock, and ciprofloxacin MICs were determined using Etest w methods (AB Biodisk, Solna, Sweden) in duplicate on separate occasions.
PD and statistical analyses
Cases in which ciprofloxacin was initiated within 24 h of the positive blood culture were used for the PD analysis. Ciprofloxacin pharmacokinetics were estimated for each patient using the population pharmacokinetic model derived by Forrest et al. 11 in an acutely ill population with an age of 68+11 years, body weight of 70+17 kg and CL CR of 63+30 mL/min/1.73 m 2 . Total ciprofloxacin clearance (CL T , L/h) was calculated for each patient using: 
Monte Carlo simulation
Monte Carlo simulation (SYSTAT w , version 12) was used to evaluate ciprofloxacin dosing and PD target attainment in a patient population with Enterobacteriaceae BSI. A cohort of 5000 study subjects was generated using the 'real patient' data collected in our study. Body weight and CL CR were modelled using log normal distributions with upper and lower limits from the clinical data. Ciprofloxacin doses of 200 mg intravenously (iv) every 12 h (low dose), 400 mg iv every 12 h (standard dose) and 400 mg iv every 8 h (high dose) were tested. Doses were reduced for renal impairment at CL CR ,30 mL/min as per the manufacturer's recommendations. The pharmacokinetic model referenced previously was used to simulate AUC 24 for each regimen in each of the 5000 subjects.
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The probability of target attainment (PTA) at each MIC was calculated as the fraction of the population achieving the AUC 24 /MIC target. Cumulative target attainment (CTA), representing the overall PD performance of each regimen, was then calculated by multiplying the PTA at each ciprofloxacin MIC by the fraction of isolates in that MIC category as per the MIC distribution in our study, and adding the values.
Results
Clinical cases
Two hundred cases of Enterobacteriaceae BSI were identified and 178 cases were included in the study. Two patients died within 48 h of their positive blood culture, and 20 isolates could not be retrieved. Forty-two (n¼ 42) of the 178 cases were included in the PD analysis. Characteristics of all cases are detailed in Table 1 . Approximately 39% were male with an average age of 66.5 years, weight of 72.6 kg and CL CR of 62.4 mL/min/1.73 m 2 . Although 62.9% of infections were community acquired, almost a quarter of patients were admitted to the intensive care unit. Escherichia coli was the most prevalent pathogen (62.4%) followed by Klebsiella spp. (28.7%). The blood isolate was also cultured from the urinary tract in 50.6% of cases and intra-abdominal wounds in 25.8% of cases. The ciprofloxacin MIC distribution is shown in Figure 1 
Zelenitsky and Ariano
PD and statistical analyses
Characteristics of the cases included in the PD analysis are also detailed in Table 1 . Although significantly more cases had the blood isolate also cultured from the urinary tract, the overall pathogen and ciprofloxacin MIC distributions (Figure 1b) for those cases included in the PD analysis were not significantly different from the other cases.
In the PD analysis, the mean ciprofloxacin AUC 24 was 41.7+14.1 mg . h/L and the median AUC 24 /MIC was 2030 (831 -3100). Eighteen of 42 cases (42.9%) received concurrent b-lactam therapy. Thirty-four cases (81.0%) had documented clinical cure, whereas six (14.3%) had persistent fever and two (4.8%) had persistent blood cultures. As detailed in Table 2 , significant factors with regard to treatment failure, in order of significance, were low AUC 24 /MIC (P,0.0001), high MIC (P ¼ 0.001), male sex (P ¼ 0.002) and low AUC 24 (P ¼ 0.01). AUC 24 /MIC and its components stratified according to clinical outcome are shown in Figure 2 . Other variables including the blood isolate also cultured from a site other than the urinary tract, malignancy and larger body weight reached the P,0.1 level of significance.
In multivariate analyses, male sex was the only significant patient-related parameter, so was kept in the stepwise analysis of the MIC, AUC 24 and AUC 24 /MIC. As shown in Table 3 , low AUC 24 /MIC (P¼0.012) and high MIC (P¼0.019) remained significant whereas AUC 24 (P¼0.085) was not significant in combined analyses with male sex. The influence of ciprofloxacin resistance was also examined by excluding two cases with ciprofloxacinresistant isolates, both with documented treatment failure. Repeating multivariate analyses under these circumstances showed that AUC 24 /MIC (P¼0.038) was significant but that MIC (P¼0.78) became inconsequential in the analysis of treatment failure.
An AUC 24 /MIC breakpoint of 250 was most significant, with cure rates of 91.4% (32/35) and 28.6% (2/7) in patients with values above and below this threshold, respectively (P¼ 0.001, Ciprofloxacin pharmacodynamics in bloodstream infection Figure 3 ). In multivariate analysis, the risk of ciprofloxacin treatment failure was 27.8 times [95% confidence interval (CI), 2.1 -333] greater in those not achieving an AUC 24 /MIC ≥250 (P ¼ 0.011).
Monte Carlo simulation
The study cohort generated by Monte Carlo simulation was described by body weight (72.4+17.1 kg) and renal function (61.5+42 mL/min/1.73 m 2 ) distributions consistent with the 178 cases of Enterobacteriaceae BSI characterized in our study. The average ciprofloxacin CL T was 18.6+6.3 L/h. The probability of achieving an AUC 24 /MIC ≥250 was 0.88 with standarddose ciprofloxacin (400 mg iv every 12 h), 0.89 with high-dose ciprofloxacin (400 mg iv every 8 h) and 0.85 with low-dose ciprofloxacin (200 mg iv every 12 h). The probability of reaching the AUC 24 /MIC target of 250 stratified according to MIC is shown in Figure 4 .
Discussion
The initial study of ciprofloxacin PD in serious, predominantly Gram-negative infections by Forrest et al. 4 found better clinical and microbiological outcomes when AUIC (area under the inhibitory curve, equivalent to AUC 24 /MIC) was ≥125 (fAUC 24 /MIC of 90 -100 based on a free fraction of 70% -80%). A trial of levofloxacin in treating nosocomial pneumonia by Drusano et al. 13 described rates of bacterial eradication at an AUC 24 /MIC breakpoint in the range of 87-109 (fAUC 24 /MIC of 60-75 based on a free fraction of 62% -76%). Investigations of agents such as levofloxacin, gatifloxacin and gemifloxacin against community-acquired respiratory pathogens, primarily Streptococcus pneumoniae, reported lower fAUC 24 /MIC thresholds of 30 -50 suggesting the potential influence of the pathogen or infectious process on 'optimal' targets. 14 -16 Finally, several studies have characterized lower rates of fluoroquinolone resistance in vitro and in vivo with higher AUC 24 /MIC ranges. 17 -20 Based on these data, AUC 24 /MIC targets of ≥125 for ciprofloxacin in treating serious Gram-negative infections and fAUC 24 /MIC targets of ≥30-50 for the 'respiratory' fluoroquinolones against S. pneumoniae have been widely adopted in the research and practice settings.
Most notably, our study demonstrates the potential for improved clinical outcomes at an AUC 24 24 /MIC) in a study of cefepime and ceftazidime for serious infections largely associated with E. coli, P. aeruginosa and Klebsiella spp. An AUC 24 /MIC breakpoint of 250 was found to be significant, with cure rates of 79% and 33% in patients with values above and below this threshold, Ciprofloxacin pharmacodynamics in bloodstream infection respectively (P ¼ 0.002). Clinical success was documented in 73%, with a median AUC 24 /MIC of 14 441 and 438 in those with clinical cure and treatment failure, respectively. In comparison, our clinical cure rate was 81% with a median AUC 24 /MIC of 2309 (cure) and 194 (failure). Cefepime and ceftazidime have an estimated free fraction of 85%. Notably, both the AUC 24 /MIC and MIC were important factors in our analysis. However, when two cases with ciprofloxacinresistant isolates were removed, the MIC was no longer significant. This finding is consistent with microbiological reporting of resistance to predict treatment failure. More importantly, it demonstrates the ability of antibiotic PD to detect differences, otherwise indistinguishable, among pathogens with MICs within the susceptible range. At this level, antibiotic PD using parameters such as AUC 24 /MIC strengthen the predictive value and clinical significance of microbiological testing. However, such information is only available in the practice setting with sufficient reporting of MIC data.
The clinical application of antibiotic PD has evolved with methods such as Monte Carlo simulation that model numerous, confounding variables to predict target attainment in patient populations of interest. Such investigations have raised concerns regarding the ability of ciprofloxacin to even achieve the conventional AUC 24 /MIC target of ≥125. 22 Our previous study of ciprofloxacin for P. aeruginosa infection found that an AUC 24 /MIC ≥125 was achieved in only 0.44 and 0.58 of a patient population receiving standard (400 mg iv every 12 h) and high (400 mg iv every 8 h) doses, respectively. 9 Similar observations were reported by Burgess and Hall 23 in their analysis using published pharmacokinetic data from healthy volunteers. Inadequate ciprofloxacin PD have been demonstrated in patients with lower respiratory tract infections where targets were predicted in 55% -65% of a population with hospital-acquired pneumonia, based on 2003 and 2007 surveillance data. 24, 25 PD studies in the critically ill have also suggested exceedingly low rates of target attainment for ciprofloxacin. Conil et al. 6 concluded that an AUC 24 /MIC ≥125 was seldom achieved in intensive care patients receiving standard doses of ciprofloxacin, while others predicted that targets would only be achieved against very susceptible pathogens with MICs ,0.25 mg/L. 8 Benko et al. 26 raised concerns following an analysis of levofloxacin for ventilatorassociated pneumonia in the critically ill.
Our analysis using Monte Carlo simulation of 5000 study subjects with Enterobacteriaceae BSI predicted that 0.88 of the population would achieve an AUC 24 /MIC ≥250 with standarddose ciprofloxacin (400 mg iv every 12 h). CTA was similar at 0.89 with high-dose ciprofloxacin (400 mg iv every 8 h) and slightly lower at 0.85 with low-dose ciprofloxacin (200 mg iv every 12 h). Importantly, these predictions were based on individualized dosing, which was adjusted for CL CR ,30 mL/min as per the manufacturer's recommendations. The lack of benefit with high-dose ciprofloxacin may be unexpected, but demonstrates the value of Monte Carlo simulation in extrapolating antibiotic PD to the clinical setting. As shown in Figure 4 , the advantages of high-dose ciprofloxacin were not observed until an MIC of 0.094 mg/L, after which significant differences emerged. The MIC distribution for Enterobacteriaceae in our study was largely below the range where high-dose ciprofloxacin was beneficial. Still, it is important to note the significant potential to improve PD exposure against pathogens with higher, but still susceptible, MICs. For example, PTA was increased from only 0.29 with standard-dose ciprofloxacin to 0.72 with high-dose ciprofloxacin at an MIC of 0.19 mg/L. Furthermore, the probability of reaching an AUC 24 /MIC ≥250 at an MIC ≥0.25 mg/L was low regardless of dose.
A limitation of our study was the small size of the PD subset. Furthermore, the significant breakpoint of 250 was based on an AUC 24 /MIC distribution of relatively high values as discussed previously. Although MIC data were measured, ciprofloxacin serum concentrations were simulated using a population pharmacokinetic model selected for characteristics relevant to our study. The original model was derived in acutely ill patients with demographics consistent with our patient population Zelenitsky and Ariano with Enterobacteriaceae BSI (mean age of 68 versus 67 years, weight of 70 versus 73 kg and CL CR of 63 versus 62 mL/min/1.73 m 2 , respectively). Furthermore, the pharmacokinetic outputs of our Monte Carlo simulation were also similar (e.g. mean ciprofloxacin CL T 18.6 versus 17 L/h). Of note, the same population pharmacokinetic model was used by Forrest et al. 11 in their initial study of ciprofloxacin PD, which may account for some of the similarities in findings. Even so, the patient populations, pathogen profiles and clinical endpoints were otherwise distinct, with our results showing potential clinical benefits at an AUC 24 /MIC breakpoint of 250 previously established for microbiological response.
This study confirms the PD parameters of ciprofloxacin that are important for optimizing the treatment of serious infections, particularly the benefits of achieving an AUC 24 /MIC ≥250, rather than the conventional target of ≥125. It also shows the relevance of dose selection in optimizing target attainment, Ciprofloxacin pharmacodynamics in bloodstream infection with important differences among pathogens, even those with MICs within the susceptible range.
